ERBB2 and breast cancer: Similar results were obtained for the various BC subtypes (HER2-positive BC: 54.4% versus 29.5% (p = 0.002), luminal: 53.3% versus 21.3% (p < 0.0001), TNBC: 24% versus 9.5% (p < 0.0001)), (Table 3).